Accellent Corp. 10-Q Quarterly Report August 2005

Investor Contact: Stewart A. Fisher	Media Contact Information: Nanette Pietroforte
EVP and CFO	FischerHealth, Inc.
(610) 409-2225	(310) 577-7870, ext. 161
stewart.fisher@accellent.com	npietroforte@fischerhealth.com

For Immediate Release

Accellent Corp. Announces Second Quarter Financial Results

Newton, MA. (August 1, 2005)

– Accellent Corp., formerly Medical Device Manufacturing, Inc. (the “Company”), a wholly owned subsidiary of Accellent Inc., announced strong results for the three months and six months ended June 30, 2005, reflecting contributions from its acquisition of MedSource Technologies, Inc. on June 30, 2004 and continued strong organic growth.

Second Quarter Financial Results

Net sales for the second quarter of 2005 increased 90% to $114.7 million compared with $60.3 million in the corresponding period of 2004. The acquisition of MedSource increased net sales by $43.9 million in the second quarter of 2005. Net income for the second quarter of 2005 was $5.9 million compared to net loss in the corresponding period of 2004 of $4.4 million. Adjusted EBITDA (1) for the second quarter of 2005 was $25.0 million compared to $11.0 million in the corresponding period of 2004. Reconciliations of non-GAAP financial measures to GAAP financial measures are provided in the financial statements accompanying this press release.

Six Months Financial Results

Net sales for the six months ended June 30, 2005 increased 99% to $223.6 million compared with $112.1 million in the corresponding period of 2004. The acquisition of MedSource increased net sales by $89.8 million for the six months ended June 30, 2005. Net income for the six months ended June 30, 2005 was $9.1 million compared to net loss in the corresponding period of 2004 of $2.0 million. Adjusted EBITDA for the six months ended June 30, 2005 was $45.0 million compared to $20.5 million in the corresponding period of 2004.

Pro Forma Financial Results (2)

Second Quarter Pro Forma Financial Results

Net sales for the second quarter of 2005 increased 6% to $114.7 million compared with pro forma net sales of $108.3 million in the corresponding period of 2004, reflecting growth in the Company’s targeted cardiovascular, endoscopic and orthopaedic markets. The impact of the Company’s facility rationalization program, which included the closing

The following information was filed by Accellent Corp. on Monday, August 1, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1297885/000110465905037838/a05-13539_110q.htm

View differences made from one quarter to another to evaluate Accellent Corp.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Accellent Corp..

Continue

Assess how Accellent Corp.'s management team is paid from their Annual Proxy

Accellent Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

CIK: 1297885
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-05-037838
Submitted to the SEC: Tue Aug 09 2005 3:25:53 PM EST
Accepted by the SEC: Tue Aug 09 2005
Period: Thursday, June 30, 2005
Industry: Surgical And Medical Instruments And Apparatus